Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ADVANCED MEDICAL SOLUTIONS GROUP PLC Earnings Release 2017

Jul 4, 2017

7467_rns_2017-07-04_74f72925-2f11-4a38-bdef-f2a86092930f.html

Earnings Release

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9919J

Advanced Medical Solutions Grp PLC

04 July 2017

4 July

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Trading Update

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces a trading update covering the six-month period 1 January to 30 June 2017.

The Group continues to make good progress and can confirm that trading for the six-month period is in line with the Board's expectations. 

Chris Meredith, Chief Executive Officer of AMS, commented: "The Board is pleased with the ongoing strong performance of the business and we are on track for the full year. We remain focused on our strategic objectives to grow organically and through acquisition, whilst delivering innovation that will benefit both patients and surgeons." 

The Group expects to publish its Interim Results for the period to 30 June 2017 on 13 September 2017.

For further information, please visit www.admedsol.com or contact: 

Advanced Medical Solutions Group plc Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597 5970
Daniel Adams / Patrick Robb

About Advanced Medical Solutions Group plc - see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 600 employees.  For more information, please see www.admedsol.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TSTLLFFRDAIVIID